MedTrace Logo

Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas

NCT02388490 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2024-09-23

Study results available
· View outcomes & findings →

Summary

This is an open-label, non-randomized, multi-center, phase II trial of brentuximab vedotin to evaluate ORR primarily in patients with EBV- and CD30-positive lymphomas.

Conditions

  • Relapsed or Refractory EBV-and CD30-positive Lymphomas

Interventions

DRUG

brentuximab vedotin

Brentuximab vedotin administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg q 3 weeks.

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    collaborator OTHER

  • SMG-SNU Boramae Medical Center

    collaborator OTHER

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Tae Min Kim, MD, PhD · Seoul National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-25
Primary Completion
2019-04-02
Completion
2019-04-02

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02388490 on ClinicalTrials.gov